Investigators Question Effect of Race on Prostate Cancer Survival

Publication
Article
OncologyONCOLOGY Vol 16 No 10
Volume 16
Issue 10

African-American patients with advanced prostate cancer survived slightly longer than white patients, according to a multi-institutional study led by Dana-Farber Cancer Institute researchers. The findings, which were reported at the 38th annual

African-American patients with advanced prostate cancer survived slightlylonger than white patients, according to a multi-institutional study led byDana-Farber Cancer Institute researchers. The findings, which were reported atthe 38th annual meeting of the American Society of Clinical Oncology, contradictthe conventional notion that African-Americans with the disease die sooner.

The data were drawn from a pooled analysis of four randomized clinical trialsin men with advanced prostate cancer that no longer responded to hormonetreatments. On average, African-Americans in the trials survived for median of15 months, whereas whites survived for a median of 14 months.

"This is evidence that African-Americans do just as well as whites whenthey’re treated within the context of a clinical trial," said Timothy D.Gilligan, md, a genitourinary oncologist at Dana-Farber. "This shoulddiscourage a pessimistic approach to prostate cancer in African-Americans inthis setting."

Treatment Discrepancies

The finding, said Dr. Gilligan, challenges epidemiologic evidence, which hassuggested that prostate cancer is more aggressive in African-Americans than inwhite men. Studies have shown that African-Americans typically are diagnosedwith more advanced disease and have a higher mortality rate than whites. Dr.Gilligan said differences in treatment could explain the discrepancy.

The researchers from several institutions including Dana-Farber, DukeUniversity, the University of Maryland, the University of California at SanFrancisco, and the University of Chicago pooled the outcomes of four trials ofseveral different treatments for hormone-refractory prostate cancer. A total of844 white men and 144 African-American men were enrolled in the studies. Theiraverage age was 71 years, and 90% had metastases to other organs.

Related Videos
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.
Related Content